Cargando…
Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
There is no effective clinical therapy for triple-negative breast cancers (TNBCs), which have high low-density lipoprotein (LDL) requirements and express relatively high levels of LDL receptors (LDLRs) on their membranes. In our previous study, a novel lipid emulsion based on a paclitaxel–cholestero...
Autores principales: | Ye, Jun, Xia, Xuejun, Dong, Wujun, Hao, Huazhen, Meng, Luhua, Yang, Yanfang, Wang, Renyun, Lyu, Yuanfeng, Liu, Yuling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003597/ https://www.ncbi.nlm.nih.gov/pubmed/27601899 http://dx.doi.org/10.2147/IJN.S113638 |
Ejemplares similares
-
In vitro antineoplastic activity in triple-negative breast cancer cell line and in vivo
por: Madeira, Klesia, et al.
Publicado: (2014) -
SAT-145 Cholesterol Uptake as a Critical Vulnerability in Triple Negative Breast Cancer
por: O’Neill, Kathleen
Publicado: (2020) -
Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022) -
A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023) -
Connexin 43 Modulates the Cellular Resistance to Paclitaxel via Targeting β-Tubulin in Triple-Negative Breast Cancer
por: Fu, Yun, et al.
Publicado: (2020)